Drug Wastage Billing Rules for Infusion Practices

JW and JZ modifiers used to be a formatting detail on drug claims. Now they're the deciding factor in whether a single-dose vial claim gets paid at all. Infusion practices that treat them as paperwork instead of revenue mechanics are either leaving reimbursable drug cost on the table or generating false claims without realizing it, and CMS has built enforcement that catches both.

How the JW/JZ enforcement timeline turned documentation into a payment gate

JW isn't new. Medicare Part B has required it on discarded single-dose vial drugs since January 1, 2017, and for years, plenty of practices treated it loosely. It sat in the background as a "bill it if you remember" line item rather than a required field.

JZ changed that dynamic. CMS introduced it January 1, 2023 as voluntary, then made it mandatory on every no-waste single-dose vial claim by July 1, 2023. Together, JW and JZ closed the loophole: there's no longer a neutral option. Every single-dose vial line has to say something, either waste happened or it didn't.

Then came the part that actually hurts. Starting October 1, 2023, Medicare Administrative Contractors began returning non-compliant claims as unprocessable. Not denied, returned. That distinction matters more than it sounds like it should. A denial gives a practice something to appeal. A return gives nothing, no payment event, no adjudication, just a claim bounced back as if it never existed. This isn't catching a handful of stray claims, either. It's running at scale, catching a meaningful volume of drug claims every day across the Medicare system.

2026 tightens the screws further. CMS is moving to mandatory modifier use across all eligible drugs, stricter unit-level validation against the vials actually opened, more frequent checks against acquisition cost, and wider audit triggers for drugs known to carry wastage risk. CMS has also named infusion billing a high-risk area for 2026, and that's not a coincidence sitting next to the modifier changes. It's the same enforcement push wearing two hats.

Behind all of it sits the Discarded Drug Refund Program, created under Section 90004 of the Infrastructure Investment and Jobs Act. Starting with 2023 data, manufacturers owe CMS a refund whenever a drug's discarded amount exceeds 10% of its total allowed charges. That refund calculation runs entirely on JW and JZ claims data. So CMS isn't just protecting claim integrity anymore. It has a financial reason, backed by law, to want that modifier data complete and accurate. That's why the automated edits aren't going away or softening. They can't.

The two revenue losses that follow from getting the modifier wrong

Getting JW/JZ wrong doesn't produce one kind of loss. It produces two, and they don't behave the same way.

Omit JW when waste actually occurred, and the practice eats the drug cost with nothing to show for it. The vial was opened, the discarded portion was real, acquisition cost was paid, and no claim line exists to recover any of it. That money is just gone.

Omit both modifiers entirely on a single-dose vial claim, and the damage widens. The whole claim returns unprocessable, not just the wastage portion. On a buy-and-bill drug, that's a real problem: per-encounter drug costs on high-cost biologics can run into the tens of thousands of dollars, and a practice fronting that cost is exposed the moment reimbursement stalls. Even a short delay creates cash-flow pressure that a smaller practice feels immediately.

Then there's the resubmission grind. A returned claim has to be corrected and refiled before the payment clock even starts again. Multiply that across dozens of claims a month, and it's not a minor inconvenience anymore, it's an administrative backlog eating staff time that should be going toward the next batch of claims.

The mirror-image risk sits on the other side: billing JW when no waste actually happened is a false claim, full stop. Practices that let systems auto-populate JW without checking whether the discard was real are walking into audit and recoupment exposure. That's a different category of consequence than a documentation gap. It's a compliance problem with teeth.

Where practices most commonly bill waste they did not actually have

At ASHP Midyear 2024, a live audience poll found that 70% of respondents said their practice auto-billed for drug waste. The presenter flagged that number as a warning sign, not a success metric, because automated systems generally can't confirm that waste actually happened. They just assume it based on vial size.

Here's the scenario that exposes the flaw: a vial holds a set quantity, two patients each receive half, and no waste occurs at all. If a system bills JW on either claim because the vial "looks like" a single-dose vial that should generate waste, that's a false claim. Not a technical foul. A false claim.

This isn't a hypothetical edge case. It's the direct, predictable result of billing logic built around vial size instead of documented discard. Any practice running that kind of system is likely generating false claims across a meaningful share of its encounters, and the risk compounds with scale rather than staying flat.

2026's tighter unit-count validation against vials actually opened makes this worse for anyone still doing it this way. A pattern of JW claims that don't reconcile with vial-level documentation is exactly the kind of signature that trips an audit trigger. The fix isn't to stop billing wastage. Wastage revenue is legitimate and worth capturing. The fix is verifying discard at the point of administration, every time, before the modifier gets applied.

What the medical record must show to support a JW claim through an audit

An auditor reviewing a JW claim wants two numbers: what was administered, and what was discarded. Both need to live in the medical record, documented at the time of the encounter, not reconstructed afterward when a payer comes asking questions. Post-hoc documentation doesn't hold up.

Vial-level tracking is non-negotiable. Which vial got opened, what dose came out of it, what was left over. A chart note that just says "waste occurred" without a number attached doesn't clear the bar. Auditors are comparing billed units against what the vial size could physically have contained, and administered-plus-discarded needs to reconcile with that package size cleanly.

This is exactly what the 2026 CMS validation changes are built to check: units billed against vials opened. A practice without per-vial documentation has no way to reconstruct that math after the fact. The record either shows it at the time or it doesn't exist.

The split-vial case makes this even more concrete. When the same vial serves two patients, only per-patient, per-draw documentation can tell an auditor the difference between a legitimate no-waste claim and a false JW claim. Without that granularity, the audit can't distinguish the two scenarios, and that ambiguity gets resolved against the practice, not for it.

None of this works if clinical staff and billing staff are operating off separate records. The clinician documenting the draw and the biller applying the modifier need to be looking at the same information. Disconnected workflows are where modifier mismatches come from, and modifier mismatches are exactly what the automated edits are designed to catch.

How J-code unit accuracy intersects with wastage billing on the same claim line

J-codes carry the drug, the form, and the per-unit quantity. Wastage modifiers sit on top of that foundation, which means an error in the unit count can undercut a perfectly correct modifier choice.

CMS Q1 2025 data put it plainly: more than 14% of outpatient claim denials involving J-codes traced back to erroneous billing units. That's the single most common failure point on drug claims, ahead of modifier issues on their own. On high-cost biologics like infliximab (J1745) and other monoclonal antibodies, unit errors draw more than a denial. They can pull OIG audit attention and open the door to payment recovery efforts.

The wastage connection is direct. The administered units and the discarded units on a JW claim have to add up to the total drawn from the vial. Get the administered unit count wrong, and the wastage math built on top of it is wrong too, even if the modifier itself was the right one to choose.

There's a quieter failure mode here as well: J-code descriptors and unit definitions update every quarter. A practice running billing logic that hasn't kept pace can apply the correct modifier to a claim built on an outdated unit definition. The modifier's right. The claim still isn't.

The 2026 reconciliation requirement, units billed against vials opened, catches both problems in the same pass. A unit error and a modifier mismatch both show up as the same kind of red flag: numbers that don't add up to what the vial could have held.

What an operationalized wastage billing workflow looks like at the claim level

Revenue cycle control for infusion drugs doesn't start when the claim gets built. It starts at scheduling and at the bedside. By the time billing touches the claim, the modifier decision has already been made, correctly or not, somewhere upstream.

Step one is clinical, not administrative. The clinician administering the drug records the dose drawn, the dose given, and the amount discarded, in the medical record, at the point of care. That's a documentation task that belongs to clinical staff, not a billing afterthought.

Step two covers preparation. If a billing supplier prepares the drug before it reaches the patient, any discard that happens during that preparation step needs its own documentation. The 2025 extension of JW/JZ obligations to non-administering billing suppliers made this a required capture point, not an optional one.

Step three is the claim build itself: JW goes on when a documented discard exists, JZ goes on when the record confirms nothing was wasted. The modifier gets derived from what's in the chart, never assumed from the size of the vial. On the claim, the administered quantity sits on the primary J-code line, and the discarded quantity sits on a separate line carrying the same J-code plus the JW modifier. Two lines, not one folded into the other.

Split-vial situations need an explicit checkpoint. When one vial serves more than one patient, each draw gets documented separately, and the sum of every draw has to reconcile with the vial's total quantity before any JW claim goes out. Skip that check and the practice is back to guessing.

Automated systems that populate JW off vial size instead of documented discard need to be rebuilt. Given that 70% of ASHP Midyear 2024 poll respondents described doing exactly this, it looks less like a scattering of individual mistakes and more like a widespread system design flaw. When a wastage claim comes back denied or returned, the fix can't stop at correcting the claim, either. It has to trace back to wherever the documentation broke down, because a billing patch alone won't stop the same gap from reappearing on the next encounter. Infusion-specific revenue cycle operations, the ones built around J-codes and buy-and-bill from the ground up, tend to close that loop between clinical charting and claim-level modifiers in a way generalized billing workflows usually don't.

Why the accuracy bar on wastage billing will continue rising and what that means for practice operations

The Discarded Drug Refund Program gives CMS a permanent, structural reason to demand clean JW/JZ data, separate from any single practice's claim history. Manufacturer refunds are calculated off aggregate modifier data, so CMS needs that data pool complete and accurate on an ongoing basis, not just during an audit cycle. This pressure doesn't ease up when enforcement priorities shift elsewhere, then. The refund math needs the data year over year.

Payer audit activity generally has been climbing too, up roughly 30% year over year through the first three quarters of 2025, and infusion billing sits right at the center of that trend given CMS's own high-risk designation for 2026.

The two failure modes carry different weights. Over-claiming waste risks false claims, recoupment, and audit exposure, and that's a heavier consequence than under-claiming, which just costs lost reimbursement. Neither is acceptable, though, and neither disappears just because a practice is more scared of one than the other.

Practices that keep treating JW/JZ as a box to check will keep hitting both problems: missed revenue on legitimate wastage, and false claims generated on wastage that never happened. That's not a training issue. It's a workflow issue, and it won't fix itself with a memo reminding staff to be careful.

The upside is real, though, and worth sitting with. Legitimate drug wastage on high-cost biologics is reimbursable cost that plenty of practices are currently absorbing simply because the modifier never got applied. Recovering it doesn't require a single new payer contract or negotiation. It requires documentation that's accurate at the point of care and a claim built to match it. Treat wastage billing as a revenue discipline, built into clinical charting, claim-line reconciliation, and denial feedback, and it's the only version of this that holds up under the scrutiny CMS has made clear is only getting sharper from here.